Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cytapheresis: the first 25 years.

J P Isbister

    Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis
    |February 1, 1997
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Descriptive characteristics and in-hospital mortality of critically bleeding patients requiring massive transfusion: results from the Australian and New Zealand Massive Transfusion Registry.

    Vox sanguinis·2017
    Same author

    Evaluation of clinical coding data to determine causes of critical bleeding in patients receiving massive transfusion: a bi-national, multicentre, cross-sectional study.

    Transfusion medicine (Oxford, England)·2016
    Same author

    Improving outcomes for hospital patients with critical bleeding requiring massive transfusion: the Australian and New Zealand Massive Transfusion Registry study methodology.

    BMC research notes·2016
    Same author

    What factors contribute to hospital variation in obstetric transfusion rates?

    Vox sanguinis·2014
    Same author

    Elucidating the clinical characteristics of patients captured using different definitions of massive transfusion.

    Vox sanguinis·2014
    Same author

    Comparing apples with oranges: A. M. Beliaev, R. J. Marshall, et al. (2011). 'Clinical benefits and cost-effectiveness of allogeneic red-blood-cell transfusion in severe symptomatic anaemia.' Vox Sang.

    Vox sanguinis·2012
    Same journal

    Apheresis therapy for living-donor liver transplantation: experience for apheresis use for living-donor liver transplantation at Kyoto University.

    Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis·2002
    Same journal

    Dextran sulfate (Selesorb) plasma apheresis improves vascular changes in systemic lupus erythematosus.

    Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis·2002
    Same journal

    Improvements in artery occlusion by low-density lipoprotein apheresis in a patient with peripheral arterial disease.

    Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis·2002
    Same journal

    A case of acute hepatic insufficiency treated with novel plasmapheresis plasma diafiltration for bridge use until liver transplantation.

    Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis·2002
    Same journal

    A case of nephrotic syndrome due to lupus nephritis which was controlled with low-density lipoprotein apheresis.

    Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis·2002
    Same journal

    Plasma exchange for hypertriglyceridemic acute necrotizing pancreatitis: report of two cases.

    Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis·2002
    See all related articles

    Therapeutic cytapheresis, initially for granulocytes, now mainly removes hemopoietic cells. While effective for chronic myeloid leukemia, its use is limited by standard therapies for most hematological diseases.

    Area of Science:

    • Hematology
    • Biomedical Engineering

    Background:

    • In vivo blood cell separators were developed for granulocyte collection in septic neutropenia.
    • This technology evolved, finding primary use in apheresis procedures beyond granulocyte collection.

    Discussion:

    • Blood cell separators excel at removing large quantities of normal or abnormal hematopoietic cells.
    • Early applications in chronic myeloid leukemia showed leukapheresis as a viable definitive therapy.
    • Cytapheresis is now limited to specific circumstances due to effective standard therapies for most hematological malignancies.

    Key Insights:

    • Therapeutic cytapheresis has evolved significantly from its original purpose.
    • The efficacy of blood cell separators is well-established for specific hematological conditions.

    Related Experiment Videos

  • Current indications for therapeutic cytapheresis are narrow but critical.

    • Outlook:

    • Further research may explore novel applications for cytapheresis in hematological disorders.
    • Optimizing cell separation techniques could expand therapeutic possibilities.
    • Integration with existing treatment protocols remains a key consideration.